Organization | Goldman, Butterwick, Fitzpatrick and Groff

Goldman, Butterwick, Fitzpatrick and Groff Report issue

Academic/Hospital Phase 2 Phase 4

Organization Overview

First Clinical Trial

2015

NCT02446223

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2022

Timeline

NOW

Now

Alternative names

DCLA | Goldman, Butterwick, Fitzpatrick and Groff

Active Ingredients

Drugs in Phase 4 Trials (5)

aminolevulinic acid (levulan) (1 trial)

deoxycholic acid (kybella) (2 trials)

ingenol mebutate (picato) (1 trial)

tretinoin (Retin-A) (1 trial)

triamcinolone (kenalog) (3 trials)

Drugs in Phase 2 Trials (1)

sodium tetradecyl sulfate (Sotradecol) (1 trial)

Drugs in Other Trials (3)

cetirizine (zyrtec) (1 trial)

hydroxyapatite silica (1 trial)

silicone (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Keratosis (Phase 4)

Keratosis, Actinic (Phase 4)

Obesity (Phase 4)

Overview

Highest Phase: Phase 4
# of Trials: 9
# of Trial APIs: 9